A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh‐frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura

Mintz, Paul D.; Neff, Anne T.; MacKenzie, Malcolm R.; Goodnough, Lawrence T.; Hillyer, Christopher D.; Kessler, Craig M.; McCrae, Keith R.; Menitove, Jay E.; Skikne, Barry S.; Damon, Lloyd E.; Lopez‐Plaza, Ileana; Rouault, Charles L.; Crookston, Kendall P.; Benjamin, Richard J.; George, James N.; Lin, Jin‐Sying; Corash, Laurence; Conlan, Maureen G.

doi:10.1111/j.1537-2995.2006.00959.x

Cited by 91 publications

(81 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The activity remained low and the inhibitor persisted at early relapse. The improvement of ADAMTS-13 activity or resolution of the inhibitor may not be predictive of remission of idiopathic TTP [22].…”

Section: Discussionmentioning

confidence: 99%

Infection as a cause of early relapse in patients recovering from thrombotic thrombocytopenic purpura

Illoh

2007

J of Clinical Apheresis

View full text Add to dashboard Cite

Thrombotic thrombocytopenic purpura (TTP) is a rare but severe disorder characterized by hemolytic anemia, thrombocytopenia, fever, renal failure, and neurologic manifestations. Plasma exchange is the most effective treatment for this condition reducing mortality from 90% in untreated patients to 10%. However, infections acquired during the course of therapy could lead to early relapse of TTP. In this case report, we report three patients with TTP who initially responded well to plasma exchange treatments but suffered early relapses following bacterial infections. All these patients achieved remission once appropriate antibiotic therapy was instituted although one patient eventually received four courses of rituximab. This report emphasizes the need to be vigilant for new infections especially urinary tract infections in TTP patients undergoing plasma exchange. Instituting appropriate antibiotic therapy once an infection is suspected may reduce the need for prolonged plasma exchange procedures and extended hospital stay.

show abstract

Section: Discussionmentioning

confidence: 99%

Infection as a cause of early relapse in patients recovering from thrombotic thrombocytopenic purpura

Illoh

2007

J of Clinical Apheresis

View full text Add to dashboard Cite

show abstract

“…This uses photochemical treatment, binding DNA and RNA, inactivating viruses, bacteria and leucocytes. It retains critical levels of coagulation proteins and ADAMTS 13 [16] and in a randomised phase III controlled trial, it has been shown to be equally efficacious and safe to standard FFP in acute TTP [17].…”

mentioning

confidence: 99%

Trends in the diagnosis and management of TTP: European perspective

Scully¹

2014

Transfusion and Apheresis Science

View full text Add to dashboard Cite

“…The 3 phase III clinical studies covered the treatment of congenital coagulopathies, acquired coagulopathies, as well as therapeutic plasma exchange for thrombotic thrombocytopenic purpura (TTP). These studies have demonstrated that the INTERCEPT treated plasma units are comparable to the conventional plasma units in terms of safety and efficacy in the support of the patients [20][21][22].…”

Section: Clinical Experiencementioning

confidence: 90%

Update on pathogen inactivation treatment of plasma, with the INTERCEPT Blood System: Current position on methodological, clinical and regulatory aspects

Irsch¹,

Seghatchian

2015

Transfusion and Apheresis Science

View full text Add to dashboard Cite

A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh‐frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura

Abstract: The comparable results between treatment groups observed from this small trial suggest that TPE with PCT FFP was safe and effective for treatment of TTP.

Cited by 91 publications

References 43 publications

Infection as a cause of early relapse in patients recovering from thrombotic thrombocytopenic purpura

Infection as a cause of early relapse in patients recovering from thrombotic thrombocytopenic purpura

Trends in the diagnosis and management of TTP: European perspective

Update on pathogen inactivation treatment of plasma, with the INTERCEPT Blood System: Current position on methodological, clinical and regulatory aspects

Contact Info

Product

Resources

About